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Langerhans cell histiocytosis (LCH) is a disease characterized 
by Langerhans cell infiltration of skin and bone, with its most 
severe form manifested by multifocal infiltration of many 
organs. The etiology is unknown, although viral infection 
has been proposed as a potential pathogenic factor. Human 
herpesvirus 6 (HHV-6), a recently described member of the 
human herpesvirus family, has been associated with atypical 
or malignant lymphocytic processes, and immune disorders. 
Based on these observations, we suspected that HHV -6 may 
playa role in the pathogenesis of LCH. 
Lesional tissue of 30 patients with LCH was retrospec-
tively examined for the presence of HHV -6 by using the 
polymerase chain reaction. Tissue specimens from 63 pa-
tients with other benign and malignant histiocytic and lym-
phocytic diseases served as controls. In addition, all speci-
mens were examined with control primers specific for herpes 
Langerhans cell histiocytosis (LCH), formerly called his-tiocytosis X (HX), is a disease characterized by Langer-hans cell infiltration of skin and bone, with its most severe form manifested by multi focal infiltration of many organs. The etiology is unknown and there is no 
specific therapy [1]. Immune dysfunction [2-4] infection [5 - 7] and 
neoplasia [8,9] have all been proposed as potential pathogenic 
mechanisms in this disease, but there is no consistent evidence for 
any of these factors, despite numerous investigative efforts. 
Viruses have long been suspected as potential etiologic agents of 
LCH [6,7,10,11]. Viral infection has been proposed as a possible 
stimulus of poorly regulated activation of histiocytes, and an un-
usual host response to viral infection postulated to account for the 
immunologic abnormalities often seen in the disease. Viral infec-
tions have been shown to influence Langerhans cell distribution in 
tissues [12-14] and Langerhans cells have been reported to act as 
[
otent activators of human T cells in herpes simplex virus infection 
15]. 
Human herpesvirus 6 (HHV -6) is a recently described member of 
the human herpesvirus family and is the etiologic agent of the 
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simplex virus (HSV). HHV-6 DNA was detected in lesions 
of 14 of 30 patients with LCH (47%). On clinical subgroup 
analysis, HHV-6 DNA was found in 10 of 16 patients with 
extraosseous disease (63%) and in four of 14 patients with 
disease limited to bone (29%). In each case, the prevalence of 
HHV-6 in LCH lesions was statistically significant, when 
compared to the control population. HSV DNA was not 
found in any of the LCH or control specimens. Although the 
presence of a virus alone does not establish a causal role in the 
disease, it supports the possibility of an etiologic relationship. 
From this study, we emphasize the need for further investi-
gation of the potential HHV -6 - mediated pathogenesis of 
LCH. Key words: polymerase chain reaction/histiocytosis 
X/eosinophilic granuloma/DNA. ] Invest Dermatof 101: 
642-645,1993 
childhood exanthem, roseola [16,17]. The seroprevalence ofHHV-
6 in the normal poeulation is high, most individuals being infected 
as children [18-20J, the population where LCH is most frequently 
found. HHV -6 was originally isolated from a small group of pa-
tients, all with lymphoproliferative disorders [21]. and a number of 
subsequent studies have provided indirect evidence for a causal asso-
ciation of ~HV-6 v.:ith atypical or malignant lymphocytic pro-
cesses, and Immune disorders [22-25]. The target cell for this virus 
appears to be primarily the T lymphocyte [26]' although latent 
infection of monocytes/macrophages has also been reported [27]. 
Based on these observations, we suspected that HHV -6 may play 
a role in the pathogenesis of LCH. To test this hypothesis, we 
ret.rospectively examined the tissues of 30 patients with LCH for 
eVIdence of HHV -6 lIlfectlOn by means of the polymerase chain 
reaction (PCR) and compared the prevalence of the vims in LCH to 
that in other histiocytic and lymphocytic diseases. 
MATERIALS AND METHODS 
Subjects Formalin-fixed, paraffin-embedded biopsies of involved tissu~ 
(i.e., skin, bone, lung, lymph node) from 30 patients who carried the patho-
logic diagnosis of LCH were obtained from the Denver Children's Hospital 
and the U.niversity of Colorado ~ealth Sciences Center. Light microscopy 
of all specimens was re-revlewed mdependently by both a pathologist (HW) 
and dermatologist (WW) to confirm the pathologic diagnosis. Both review-
ers were blinded to each other's readings. The patients' medical records were 
reviewed to confirm the recorded biopsy site and obtain details of the clinical 
presentation of disease to ensure inclusion of only patients with LCH. Be-
cause LCH has protean clinical manifestations, the nomenclature used in 
describing its various forms can be confusing. For our study, LCH was 
divided into two subsets: 1) HX, defined by involvement of skin and/ or 
multiple organ systems, including the Lctterer-Siwe and Hand-Schuller. 
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Table I. Clinical Profile of Cases of Extraosseous Langerhans Cell Histiocytosis (HX) 
Case Patient's Age Sites of Involvement Biopsy Site(s) HHV-6 Status 
I 
II 
III 
IV 
16 years 
1 year 
Skin, bone, liver, lung, LNs," mucosa 
Skin, bone, soft tissue, otitis 
LN 
Skin 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Negative 
Negative 
Negative 
Negative 
V 
2 years 
23 years 
1 month 
40 years 
1 year 
2 years 
5 years 
1 year 
Skin 
Lung 
Skin 
Skin, mucosa 
Skin, bone, soft tissue, otitis 
Bone, soft tissue, LNs, otitis 
Skin 
Bone, soft tissue, mucosa 
Skin 
Endobronchial 
Skin 
Skin 
Soft tissue mass 
Soft tissue mass 
Skin 
VI 
VII 
VIII 
IX 
X 
XI 
XII 
XIII 
XIV 
6 months 
11 months 
5 months 
2 years 
Skin, bone, lung, liver, spleen, LNs, bone marrow 
Skin, bone, mucosa, LNs, otitis 
Soft tissue mass 
Skin 
Skin, LN 
Skin Skin 
Done, soft tissue, exo.phthalmous, 
otitis, diabetes insipidus 
Soft rissue mass 
XV 
XVI 
--:LN, lymph node. 
19 months 
2 years 
Skin, LNs, otitis 
Lung, liver, spleen, LNs 
Ch . stian syndromes, and 2) eosinophilic granuloma (EG), defined by single 
n ultiple bone lesions and no other disease manifestations. Sixteen of the 
or me specimens were from patients with HX and 14 tissue specimens were 
nssu f · · h EG b e lesions 0 patlents WIt . o~ixty-three control biopsies of benign a?d malignant histiocytic a.nd lym~ 
h ytic diseases of the skm were obtamed from the same mstltutlons 
p °hCology departments . Three tissue specimens were obtained from the 
fat nal skin of patients with congenital self-healing reticu lohistiocytosis (~~oHR), one from lesional skin of a 'patient with benign cephalic h~stiocyto­
sis (BCH), nine frmn lymphomatmd papuloSlS, ten from pItyriaSIS lIchen-
. d s et varioliformls acuta (PLEVA), 38 from cutaneous T-cell lymphoma o~;CL), one from the lymph node of a patient with severe combined 
( une deficiency dIsease (SCID), and several skm and lymph node bIOpSIes 
'&0: a patient with SCID with reticuloendothcliosis and eosinophilia 
(Omenn's disease) . 
Extraction of ON A Thirty 5-J-fm sections were cut from each block and 
1 d into sterile tubes. The sectIons were deparaffimzed wIth xylene and i;3~o ethanol and incubated overnight at 65 ·C in 10,ul Proteinase K (10 
mimi; BRL, Gaithersburg, MD) and 90,ullysis buffe~ (10 mM Tm, 1 mM et~ylenediamine tetraacetlc aCId (EDTA), 0.1 % sodl~m dodecylsulfate). 
DNA was then isolated by two successIve phenol extractIons, precIpItated III 
hanoi, resuspended in 100,ul sterile TE (10 mM Tris-HCl, IlnM EDTA, ~~ 7.5) and stored at -20·C until studied. 
DNA ~plification Amplification of DNA was accomplished using the 
lymerase chain reaction (PCR). The HHV-6 primers used were 25-base-~ir 01 igonucleotides that amplify a 223 - base-pair portion of the 13R open 
P ading frame of the HHV-6 strain Ul102 genome [28]. These have been 
re eviousLy shown to be specific for HHV-6 [29] . Primers that amplify a 
i;O -base-pair portion of the human beta-globin (BG) gene were used to 
verify the quality of DNA extracted from each speCImen, as preVIOusly 
described [30]. HHV-6-positive control DNA was obtained by standard 
henol extraction ofHHV-6 strain GS-infected HSD-2 cells [31]. Negative ~ontrol DNA was extracted from uninfected HSB-2 cells. Five microliters of 
each sample were added to 25,ul of reaction mixture containing 0.6 units of 
Taq polymerase (Perkin Elmer Cetus, Norwalk, CT), prepared according to 
rhe recommendations of the Cetus Corporation. The thermocycling proce-
dure consisted of initial denaturation at 94 · C for 12 min, 35 cycles of 
denaturation at 94·C for 1 min, annealing at 58 · C for 1.5 min, and exten-
sion at 72 · C for 1.5 min, followed by a final extension at n ·c for 10 min. 
As an additional control, all specimens were also examined for the pres-
ence of HSV DNA using the PCR [32] . The primers t1Sed have sequence 
homology within both the HSV-l and HSV-2 DNA polymerase genes and 
rhe predicted amplified prod~ct ":35 224 base pairs: The PCR protocol used 
[0. amplify HSV DNA was Identical to that deSCribed for amplificatIOn of 
HHV-6 DNA. 
DNA Detection After PCR, 15,ul of amplified product was loaded into 
each of the lanes of 8% polyacrylamide gels and separated electrophoreti-
cally. The DNA was then transferred to positively charged nylon mem-
branes (Boehringer Mannheim, Indianapolis, IN). Positive and negative 
DNA controls were included on each gel, to ensure that the amplification 
was effici.ent and that no contamination had occurred. The membranes were 
Skin 
LN 
Negative 
Negative 
hybridized at 50· C overnight with HHV -6, BG, and HSV internal oligonu-
cleotides [28,30,32] labeled nonradioactively according to the specifications 
of the DIG oligonucleotide 3' end-labeling kit (Boehringer Mannheim) . 
The membranes were washed, and bound DNA was detected by using the 
protocol recommended for the anti-digoxigenin alkaline phosphatasel 
Lumi-Phos 530 chemiluminescence system (Boehringer Mannheim). 
Statistical Analysis The proportions of HHV -6 positivity in the differ-
ent study groups were compared by a two-tailed Fisher exact test. All p values 
less than 0.05 were considered significant. 
RESULTS 
Cli~ical Profile of the Patients Sixteen patients had the diag-
noSIS ofHX. Pertinent epidemiologic and clinical data for these HX 
patients are shown in Table 1. The mean age of patients in the HX 
group was 6.2 years. 
Fourteen patients had the diagnosis of EG. Twelve of these 14 
had unifocal or solitary EG and two had multifocal EG. The mean 
age of patients in the EG group was 6.3 years. 
Detection of HHV-6 by PCR DNA bands of the anticipated 
size for BG fragments were readily detected for all patient speci-
mens and control DNA. The amplified 223-base-pair fragment of 
HHV-6 DNA was detected in 14 of 30 (47%) of the total LCH 
specimens, including both HX andEG populations (Table 11, Fig 1) . 
The control group had only three of 63 (5%) HHV-6-positive 
~peCl~ens: one SCID lymph node with a histologic appearance 
l11dlstl11g~lshable f~om LCH and two skin biopsies, one from lym-
phomatOid papuloSlS and one from CTCL. None of the patients had 
evidence of HSV DNA in any specimen (data not shown). 
The prevalence of HHV- 6 positivity in LCH was significantly 
higher than that of the control population (p < 0.001). Ten of 16 
specimen.s from ~atients with HX (63%) and four of 14 specimens 
from patients With EG (29%) were positive for HHV-6. When 
these two subpopulations ofLCH were compared independently to 
controls, both the HX patients (p < 0.001) and the EG patients 
(p = 0.02) had a significantly higher prevalence of HHV-6 in af-
fected tissues. Of note, both patients with multifocal EG were posi-
t ive for HHV-6 in affected bone. 
DISCUSSION 
LCH has not been previously linked to a specific infectious agent, 
although indirect evidence supports the possibility that viral infec-
tion might be the precipitating event for the clinical , histologic, and 
immunologic pathology observed [6,7,11] . Viral infection has been 
shown to influence Langerhans cell distribution and function. Fol-
lowing viral vaccinations, Langerhans cells migrate from epidermis 
to dermis and regional lymph nodes [14J and increased Langerhans 
cells are present in the lymph nodes of patients with a variety of viral 
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Table II. Proportion of Cases Positive for HHV-6 
DNA by Diagnosis 
Diagnosis Number Positive/Number Tested 
LCH 
HX 
EG 
Control 
• p < 0.001 compared to control. 
• p = 0.02 compared to control. 
14/30 
10/16 
4/14 
3/63 
% 
47' 
63' 
29' 
5 
diseases [12] . In one report, Langerhans c~lls w~re found ectopically 
in the liver in viral hepatitis [13]. In HIV mfectlon, Langerhans cells 
can sU'pport viral replication and transmission to lymphocytes 
[33,34]. Langerhans cells have been shown to act as potent activa-
tors of human T cells in herpes simplex virus infection [15]. Hence, 
the proliferation of Langerhans cells in LCH may be a physiologi-
cally appropriate, but clinically pathologic, response to a viral infec-
tion. 
The immune abnormalities seen in LCH could also be explained 
by viral infection. The most consistent abnormalities seen have been 
a decrease in number and function of suppressor T cells and dysmor-
phic changes in the thymus, although monocyte dysfunction and 
B-cell abnormalities, including elevated antibody levels, have also 
been reported. HIV is well known to stimulate CD8+ cells and to 
cause persistent antibody production; now there is evidence that 
HIV infection of dendritic cells may underlie both effects [35]. In 
LCH, a different virus might activate histiocytes and also impair 
immune regulation of subsequent histiocytic proliferation, by dis-
abling the suppressor T cell and pathologically amplifying the host 
immune response to the primary infection. Dysmorphic thymic 
changes seen in LCH are similar to those seen in a patient with 
congenital rubella [36] and in patients with HIV infection [37,38] 
suggesting that thymic and T-cell dysfunction could be a direct 
effect of viral infection. Because HHV -6, a lymphotropic virus spe-
cific for T cells [21-26]' also latently infects human monocytes/ 
macro phages [27], it would be a prime candidate agent in the initia-
tion ofLCH. 
Other histiocytic diseases have been linked to viral infection. 
Risdall et al studied 19 patients with bone marrow histiocytosis 
accompanied by prominent erythrophagocytosis and found 14 pa-
tients with active HSV infections, one with adenovirus, and one 
with Epstein-Barr virus [39]. All patients had absence of response to 
mitogens, which normalized upon recovery. Most recently, Levine 
H X1 HX2 BCH POS NEG 
HHV-6 223 bp-
BG 11 Obp-
2 3 4 5 6 7 8 9 10 
Figure 1. HHV-6 detection by peR. Autoradiograph obtained after hy-
bridization of labeled probes with DNA transferred to nylon membranes, 
demonstrating the presence of both BG and HHV-6 DNA in the lesions of 
two different patients with HX (lalles 1 - 4) and the absenceofHHV-6 DNA 
in a lesion of BCH (lan es 5 alld 6). Positive and negative control DNA is 
demonstrated in lanes 7 -1 O. 
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et III studied nine patients with sinus histiocytosis with massive 
lymphadenopathy (Rosai-Dorfman disease), a disease of histiocytic 
origin usually presenting as painless cervical lymphadenopathy in 
children and young adults. Using i,., siw hybridization, the investi-
gators were able to detect HHV-6 DNA in seven of nine cases 
studied and noted that the HHV-6 sequences tended to be localized 
in lymph node sinuses that contained abnormal histiocytes [40]. III 
situ hybridization studies of LCH and control tissue might localize 
the HHV-6 DNA to a particular cell (e.g., the Langerhans cell) and 
he lp to clarify the potential pathogenic role of the virus in this 
disease. 
In summary, HHV-6 DNA was demonstrated in the involved 
tissue of 14 of 30 patients with LCH and in an even higher percent-
age of cases of multisystem HX. These results were highly signifi-
cant when compared to those obtained from the control population 
of benign and malignant histiocytic and lymphocytic diseases. Al-
though presence of a virus alone does not establish a causal role in 
any given disease, it certainly supports the possibility of an etiologic 
relationship. From this study, we emphasize the need for further 
investigation of the potential HHV-6 mediated pathogenesis of 
LCH, and also the impact ofHHV-6 infection on immune regula-
tion in the human host . 
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